Response variability to clopidogrel: is tailored treatment, based on laboratory testing, the right solution?

@article{Cattaneo2012ResponseVT,
  title={Response variability to clopidogrel: is tailored treatment, based on laboratory testing, the right solution?},
  author={Marco Cattaneo},
  journal={Journal of Thrombosis and Haemostasis},
  year={2012},
  volume={10}
}
  • M. Cattaneo
  • Published 1 March 2012
  • Biology
  • Journal of Thrombosis and Haemostasis
Summary.  Clopidogrel is an antithrombotic prodrug, whose active metabolite inhibits platelet function by irreversibly binding to the platelet receptor for adenosine diphosphate, P2Y12. Wide inter‐individual variability of response to clopidogrel has been reported in several studies: a significant proportion of treated patients (about one‐third) exhibit a suboptimal inhibition of platelet function. Genetic and environmental factors that influence the absorption and/or the extent of metabolism… 
Antiplatelet therapy : does it need laboratory monitoring ?
TLDR
Antiplatelet therapy is heading towards an opposite direction compared to anticoagulant therapy, thanks to the introduction in the clinical practice of new drugs with very good and predictable bioavailability, such as low molecular weight heparins which do not need laboratory monitoring, and have progressively replaced unfractionated heparin.
Mechanisms of variability in antiplatelet agents response.
Treatment Options for Patients With Poor Clopidogrel Response
TLDR
Of the alternatives to standard dosing of clopidogrel, switching to either prasugrel or ticagrelor has the most potential benefit, but again, there is limited evidence to support this practice in patients who demonstrate high on-treatment platelet reactivity while on clopIDogrel although the evidence is somewhat more supportive in Patients who have a CYP2C19 loss-of-function variant allele.
Role of VASP Phosphorylation Assay in Monitoring the Antiplatelet Therapy
TLDR
VASP-P flow cytometric assay is emerging into the spotlight as the promising method, mostly for its specificity for ADP inhibitors, better outlook for standardising results and lesser sample manipulation compared to multiple electrode aggregometry.
Advances in the monitoring of anti-P2Y12 therapy
TLDR
An overview of the current platelet and genetic tests available is described and whether these tests will ever become used routinely is discussed, with the question remains whether any of these tests have prognostic utility with a defined therapeutic window.
High on-treatment platelet reactivity--definition and measurement.
In the last decade, several studies revealed inter-patient response variability to antiplatelet agents: patients who display negligible or no responses to these drugs are considered poor responders,
Tailored Thienopyridine Therapy: No Urgency for CYP2C19 Genotyping
TLDR
There is currently no convincing data to support that using CYP2C19*2 genotyping as a tailored anti‐P2Y12 treatment would be an effective strategy and there is no urgency for CYP1C19 genotypes in clinical practice, but strategies incorporating genotypes, phenotypes, and clinical data in a stratified and sequential approach may be more promising.
How to test the effect of aspirin and clopidogrel in patients on dual antiplatelet therapy?
TLDR
Dual antiplatelet therapy with clopidogrel and aspirin is frequently used for the prevention of recurrent ischemic events, however their value in dual therapy has not been explored.
Pharmacogenomics in cardiovascular disease: focus on aspirin and ADP receptor antagonists
TLDR
The present review outlines the panel of polymorphisms affecting the benefit of aspirin and adenosine diphosphate receptor antagonists, including novel and ongoing studies evaluating whether genotyping may be beneficial in tailoring antiplatelet therapy.
Comparison of a New P2Y12 Receptor Specific Platelet Aggregation Test with Other Laboratory Methods in Stroke Patients on Clopidogrel Monotherapy
TLDR
The new ADP(PGE1) method is a reliable test for monitoring P2Y12 receptor inhibition by platelet aggregation and showed good correlation with VASP phosphorylation and had high diagnostic efficiency.
...
...

References

SHOWING 1-10 OF 96 REFERENCES
Aspirin and Clopidogrel: Efficacy, Safety, and the Issue of Drug Resistance
  • M. Cattaneo
  • Biology
    Arteriosclerosis, thrombosis, and vascular biology
  • 2004
TLDR
“Aspirin-resistant” should be considered as a description for those individuals in whom aspirin fails to inhibit thromboxane A2 production, irrespective of the results of unspecific tests of platelet function, such as the bleeding time, platelet aggregation, or the PFA-100 system.
Resistance to antiplatelet drugs: molecular mechanisms and laboratory detection
  • M. Cattaneo
  • Biology
    Journal of thrombosis and haemostasis : JTH
  • 2007
Summary.  The definition ‘resistance to antiplatelet drugs’ should be limited to situations in which failure of the drug to hit its pharmacological target has been documented by specific laboratory
Stability of the high on-treatment platelet reactivity phenotype over time in clopidogrel-treated patients.
TLDR
The HPR phenotype is stable over time in the majority of clopidogrel-treated patients, and Comparative assessment of phenotype stability across available platelet function assays warrants further investigation.
An initial experiment with personalized antiplatelet therapy: the GRAVITAS trial.
TLDR
The GRAVITAS trial was the first large randomized, prospective trial to determine whether personalization of antiplatelet therapy based on platelet function testing actually improves 6-month clinical outcomes among patients treated with stents and the major findings were that the rate of ischemic events was low, and high-dose clopidogrel therapy had a limited effect in overcoming high platelet reactivity.
The Influence of Proton Pump Inhibitors on the Antiplatelet Potency of Clopidogrel Evaluated by 5 Different Platelet Function Tests
TLDR
Concomitant treatment with PPIs did not attenuate theAntiplatelet effect of clopidogrel in patients on dual antiplatelet therapy irrespective of the type of PPI and the used test system.
Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.
TLDR
CYP2C19*2 genotype was associated with diminished platelet response to clopidogrel treatment and poorer cardiovascular outcomes, and patients with the CYP2C 19*2 variant were more likely to have a cardiovascular ischemic event or death during 1 year of follow-up.
Can we override clopidogrel resistance?
TLDR
A novel clinical approach using pharmacodynamic and genetic information to override clopidogrel resistance is described, and this work reports 7 recent cases of stent thrombosis with demonstrated platelet resistance to clopIDogrel.
Clopidogrel-drug interactions.
CYP2C19*2 polymorphism is not the sole determinant of the response to clopidogrel: implications for its monitoring
TLDR
A vasodilator-stimulated phosphoprotein (VASP)02 study comparing the responses of 153 patients to 75 and 150 mg day maintenance doses of clopidogrel was reanalyzed after determining the 2C19*2 polymorphisms in these patients, confirming the presence of a drug–drug interaction effect.
...
...